Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Resistance to Bortezomib Develops Slowly in MCL Cells, Extends to the Class of Proteasome Inhibitors, and Is Associated with Decreased Proliferation of the Resistant Cells.

Helena Mora-Jensen, BS, Edgar G. Rizzatti, MD,PhD, Adrian Wiestner, MD,PhD

Blood (2006) 108 (11): 4397.

https://doi.org/10.1182/blood.V108.11.4397.4397

Published: 2006

Journal Articles

Bortezomib Activity Against Mantle Cell Lymphoma Overcomes Classic Mechanisms of Drug Resistance and Targets Cell Cycle Control.

Edgar G. Rizzatti, MD, PhD, Helena Mora-Jensen, BS, Elinor Lee, BS, Yuji Miura, MD/PhD, Raymond Lai, MD/PhD, Masanori Daibata, MD, Adrian Wiestner, MD/PhD

Blood (2006) 108 (11): 4393.

https://doi.org/10.1182/blood.V108.11.4393.4393

Published: 2006

Journal Articles

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Edgar G. Rizzatti, MD, PhD, Helena Mora-Jensen, BS, Raymond Lai, MD/PhD, Masanori Daibata, MD, Therese White, RN, Kieron Dunleavy, MD, Wyndham Wilson, MD/PhD, Adrian Wiestner, MD/PhD

Blood (2006) 108 (11): 830.

https://doi.org/10.1182/blood.V108.11.830.830

Published: 2006

Journal Articles

Potent Single Agent Activity and Tumor Selectivity of Bortezomib in Mantle Cell Lymphoma: First Impressions from a Randomized Phase II Study of EPOCH-Rituximab-Bortezomib in Untreated Mantle Cell Lymphoma.

Adrian Wiestner, MD, PhD, Kieron Dunleavy, MD, Edgar G. Rizzatti, MD/PhD, Hui Liu, Msc, Gerald E. Marti, MD, Therese White, RN, Wyndham Wilson, MD/PhD

Blood (2005) 106 (11): 4744.

https://doi.org/10.1182/blood.V106.11.4744.4744

Published: 2005

Journal Articles

Gene Expression Analysis Uncovers Possible Resistance Mechanisms to Bortezomib in Mantle Cell Lymphoma That Differ from Mechanisms Identified in Other Lymphoid Malignancies.

Edgar G. Rizzatti, MD, PhD, Helena I. Mora-Jensen, Eric Billings, PhD, Raymond Lai, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2005) 106 (11): 2412.

https://doi.org/10.1182/blood.V106.11.2412.2412

Published: 2005

Journal Articles

Gene Expression Profiling of Mantle Cell Lymphoma in the Leukemic Phase Reveals Aberrant Expression of Genes from the TGF-β Signaling Pathway.

Edgar G. Rizzatti, MD, Rodrigo A. Panepucci, MSc, Rodrigo Proto-Siqueira, PhD, Wilma T. Anselmo-Lima, MD, PhD, Oswaldo K. Okamoto, PhD, Roberto P. Falcao, MD, PhD, Marco A. Zago, MD, PhD

Blood (2004) 104 (11): 2048.

https://doi.org/10.1182/blood.V104.11.2048.2048

Published: 2004

Journal Articles

PRAME Protein Is Aberrantly Expressed in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

Rodrigo Proto-Siqueira, PhD, Lorena L. Figueredo-Pontes, MD, Eduardo M. Rego, MD, PhD, Edgar G. Rizzatti, MD, Fabio M. Nascimento, Rodrigo S. Abreu e Lima, MD, Roberto P. Falcao, MD, PhD, Valery Filonenko, Marco Antonio Zago, MD, PhD

Blood (2004) 104 (11): 958.

https://doi.org/10.1182/blood.V104.11.958.958

Published: 2004

NARROW

Resistance to Bortezomib Develops Slowly in MCL Cells, Extends to the Class of Proteasome Inhibitors, and Is Associated with Decreased Proliferation of the Resistant Cells.

Bortezomib Activity Against Mantle Cell Lymphoma Overcomes Classic Mechanisms of Drug Resistance and Targets Cell Cycle Control.

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Potent Single Agent Activity and Tumor Selectivity of Bortezomib in Mantle Cell Lymphoma: First Impressions from a Randomized Phase II Study of EPOCH-Rituximab-Bortezomib in Untreated Mantle Cell Lymphoma.

Gene Expression Analysis Uncovers Possible Resistance Mechanisms to Bortezomib in Mantle Cell Lymphoma That Differ from Mechanisms Identified in Other Lymphoid Malignancies.

Gene Expression Profiling of Mantle Cell Lymphoma in the Leukemic Phase Reveals Aberrant Expression of Genes from the TGF-β Signaling Pathway.

PRAME Protein Is Aberrantly Expressed in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Resistance to Bortezomib Develops Slowly in MCL Cells, Extends to the Class of Proteasome Inhibitors, and Is Associated with Decreased Proliferation of the Resistant Cells.

Bortezomib Activity Against Mantle Cell Lymphoma Overcomes Classic Mechanisms of Drug Resistance and Targets Cell Cycle Control.

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Potent Single Agent Activity and Tumor Selectivity of Bortezomib in Mantle Cell Lymphoma: First Impressions from a Randomized Phase II Study of EPOCH-Rituximab-Bortezomib in Untreated Mantle Cell Lymphoma.

Gene Expression Analysis Uncovers Possible Resistance Mechanisms to Bortezomib in Mantle Cell Lymphoma That Differ from Mechanisms Identified in Other Lymphoid Malignancies.

Gene Expression Profiling of Mantle Cell Lymphoma in the Leukemic Phase Reveals Aberrant Expression of Genes from the TGF-β Signaling Pathway.

PRAME Protein Is Aberrantly Expressed in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only